- Home
- STK vs JANX Comparison
STK vs JANX Comparison
Compare STK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.0M | 1.0B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STK | JANX |
|---|---|---|
| Price | $52.77 | $16.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $33.81 |
| AVG Volume (30 Days) | 40.6K | ★ 703.5K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | $194.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.50 | $12.12 |
| 52 Week High | $58.46 | $35.34 |
Technical Indicators
Market Signals| Indicator | STK | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 45.81 |
| Support Level | $50.58 | $15.83 |
| Resistance Level | $53.39 | $19.16 |
| Average True Range (ATR) | 1.17 | 0.88 |
| MACD | -0.30 | -0.06 |
| Stochastic Oscillator | 29.25 | 16.49 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.